Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Caribou Biosciences, Inc. is a clinical-stage biotechnology company focused on developing CRISPR genome-edited cell therapies for the treatment of cancer and autoimmune diseases. The company operates within the biotechnology and cell and gene therapy industries, with a primary emphasis on allogeneic (off-the-shelf) immune cell therapies. Its core value proposition centers on leveraging precise genome-editing technologies to improve the safety, consistency, and scalability of cell-based treatments.
Founded in 2011 as a spin-out from academic research associated with CRISPR pioneer Jennifer Doudna, Caribou initially focused on genome-editing technologies and intellectual property. Over time, the company evolved into a therapeutics-focused organization, advancing a pipeline of engineered cell therapies into clinical development. Caribou is distinguished by its proprietary chRDNA™ CRISPR genome-editing platform, which is designed to enable highly specific and multiplexed gene edits.
Business Operations
Caribou’s business operations are organized around the research, development, and clinical advancement of allogeneic immune cell therapies, primarily CAR-T cell therapies and CAR-NK cell therapies. The company does not currently generate product revenue and relies on capital from equity financing, strategic collaborations, and milestone-based payments to fund operations. Its lead programs are designed to treat hematologic malignancies and autoimmune indications by engineering immune cells to enhance persistence, reduce immune rejection, and improve safety profiles.
The company conducts research and early manufacturing internally while leveraging external partners for certain clinical trial activities and manufacturing scale-up. Caribou retains control over its core genome-editing technologies and therapeutic candidates. It has historically entered into licensing and collaboration agreements related to its CRISPR intellectual property, though its primary operational focus is now on advancing its wholly owned clinical pipeline.
Strategic Position & Investments
Strategically, Caribou is focused on advancing multiple clinical-stage programs while expanding the application of its genome-editing platform to new immune cell types and disease areas. Its lead clinical candidates include CB-010, an allogeneic anti-CD19 CAR-T therapy, and CB-011, targeting BCMA for multiple myeloma, both of which utilize extensive multiplex genome editing. The company is also developing CB-012, a CAR-NK cell therapy, reflecting its broader investment in next-generation immune cell modalities.
Caribou has made targeted investments in platform development rather than large-scale acquisitions, prioritizing internal innovation and pipeline expansion. Its strategic positioning emphasizes differentiation through precision genome editing, with the goal of achieving improved efficacy and safety compared to first-generation allogeneic cell therapies. Emerging areas of focus include autoimmune diseases and the use of genome editing to overcome immune cell exhaustion and rejection.
Geographic Footprint
Caribou Biosciences is headquartered in Emeryville, California, within the United States, and its primary operations, including research, development, and corporate functions, are based there. Clinical trials are conducted across multiple sites, primarily in North America, with participation from leading academic medical centers and oncology treatment networks.
While the company does not maintain large international operational facilities, its clinical and scientific activities have an international reach through global clinical trial participation and regulatory engagement. Caribou’s intellectual property portfolio and technology licensing arrangements also give it a presence in broader global biotechnology markets.
Leadership & Governance
Caribou is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development, guided by a strategic vision focused on translating genome-editing science into scalable, off-the-shelf therapies. The company operates under a conventional U.S. public-company governance structure, with oversight provided by an independent board of directors.
Key executives include:
- Rachel E. Haurwitz, Ph.D. – President and Chief Executive Officer
- Peter J. Costa, Ph.D. – Chief Scientific Officer
- Namir Hassan, M.D. – Chief Medical Officer
- Brian L. Cothran – Chief Financial Officer
- Robert Bell – Chief Development Officer
The leadership team emphasizes disciplined clinical execution, platform-driven innovation, and long-term value creation through wholly owned therapeutic programs rather than near-term commercialization partnerships.